NK cell-based cancer immunotherapy: from basic biology to clinical development

被引：0
作者：
Sizhe Liu
Vasiliy Galat
Yekaterina Galat4
Yoo Kyung Annie Lee
Derek Wainwright
Jennifer Wu
机构：
[1] Northwestern University,Department of Urology, Feinberg School of Medicine
[2] Northwestern University,Department of Pathology, Feinberg School of Medicine
[3] Northwestern University Feinberg School of Medicine,Robert H. Lurie Comprehensive Cancer Center
[4] Northwestern University Feinberg School of Medicine,Department of Pediatrics, Stanley Manne Children’s Research Institute, Ann & Robert H. Lurie Children’s Hospital
[5] Emory University,Biology Program
[6] Northwestern University,Departments of Neurological Surgery, Medicine
[7] Russian Academy of Sciences,Hematology and Oncology, Microbiology
来源：
Journal of Hematology & Oncology | / 14卷
关键词：
NK cell; Cancer immunotherapy; Clinical trials; iPSC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Natural killer (NK) cell is a specialized immune effector cell type that plays a critical role in immune activation against abnormal cells. Different from events required for T cell activation, NK cell activation is governed by the interaction of NK receptors with target cells, independent of antigen processing and presentation. Due to relatively unsophisticated cues for activation, NK cell has gained significant attention in the field of cancer immunotherapy. Many efforts are emerging for developing and engineering NK cell-based cancer immunotherapy. In this review, we provide our current understandings of NK cell biology, ongoing pre-clinical and clinical development of NK cell-based therapies and discuss the progress, challenges, and future perspectives.
引用
收藏
相关论文
共 163 条
  • [1] Guerra N(2008)NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy Immunity 28 571-580
  • [2] Imai K(2000)Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population Lancet 356 1795-1799
  • [3] Lopez-Soto A(2017)Control of metastasis by NK Cells Cancer Cell 32 135-154
  • [4] Sakamoto N(2015)Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer J Transl Med 13 277-3057
  • [5] Miller JS(2005)Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer Blood 105 3051-959
  • [6] Rubnitz JE(2010)NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia J Clin Oncol 28 955-1789
  • [7] Iliopoulou EG(2010)A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer Cancer Immunol Immunother 59 1781-2739
  • [8] Lanier LL(1986)Natural killer cells: definition of a cell type rather than a function J Immunol 137 2735-510
  • [9] Smyth MJ(2005)Activation of NK cell cytotoxicity Mol Immunol 42 501-526
  • [10] Roda JM(2006)Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells Cancer Res 66 517-149
12345678910